Format

Send to

Choose Destination
Cancer Biomark. 2015;15(5):591-7. doi: 10.3233/CBM-150499.

TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients.

Abstract

BACKGROUND:

The significance of transketolase-like enzyme 1 (TKTL1) and p63 in the clinical progression and prognosis of gastric cancer patients has not been established.

OBJECTIVE:

This study investigated the expression of TKTL1 and p63 in gastric cancer and their clinical significance.

METHODS:

TKTL1 and p63 expression in 101 gastric cancer tissue specimens and 25 normal gastric mucosa tissues were detected by immunohistochemistry (IHC).

RESULTS:

The percentage of positive TKTL1 and p63 expression in gastric carcinomas was significantly higher than that in normal gastric mucosa tissues (P < 0.05). Positive TKTL1 and p63 expression significantly correlated with larger tumor size, deeper invasion, higher TNM stage, and lymph node metastasis (P< 0.05). The expression of TKTL1 significantly correlated with p63 expression in gastric cancer tissues (r = 0.476, P < 0.01). Univariate analysis revealed that positive TKTL1 and/or positive p63 expression correlated significantly with shorter survival and lower 5-year survival rate (P = 0.001). Cox multivariate analysis demonstrated that expression of TKTL1 and p63 is an independent prognostic factor (P < 0.05) in gastric cancer.

CONCLUSIONS:

Both TKTL1 and p63 are independent prognostic factors of the poor outcome of gastric cancer patients.

KEYWORDS:

TKTL1; gastric cancer; p63; prognosis

PMID:
26406948
DOI:
10.3233/CBM-150499
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center